Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254538 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19CA1CA2 | |
| SCHEMBL2353155 | 0.85 | MAPT (0.56) | CYP1A2CYP2C9CYP2C19CA1CA2 | |
| SCHEMBL30394742 | 0.85 | MAPT (0.56) | CYP1A2CYP2C9CYP2C19CA1CA2 | |
| SCHEMBL17796948 | 0.85 | TAS2R14 (0.48) | NPSR1ALDH1A1KIF11MEN1KMT2A | |
| SCHEMBL17827022 | 0.83 | MEN1 (0.41) | CYP1A2CYP2C9CYP2C19CA1CA2 | |
| SCHEMBL31245754 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6063344 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL5544752 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31434967 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19CA1CA2 | |
| SCHEMBL9185909 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239869-B2 | Sulfonamide compounds as voltage-gated sodium channel modulators | LUPIN LIMITED (IN) | 2019-03-26 | — | — | US | disclosed |
| CN-108349957-A | Sulfonamide compounds as modulators of voltage-gated sodium channels | 鲁平有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3344621-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | Lupin Limited (IN) | 2018-07-11 | — | — | EP | disclosed |
| US-20180186777-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2018-07-05 | — | — | US | disclosed |
| WO-2017037682-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2017-03-09 | — | — | WO | disclosed |
| EP-2582680-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| CN-102947274-A | Biphenyl substituted 1, 3-dihydro-benzoimidazol-2-ylideneamine derivatives | NOVARTIS AG | 2013-02-27 | — | — | CN | disclosed |
| WO-2011157787-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-6300352-B1 | FOR THERAPY OF ASTHMA | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| EP-0971892-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042670-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239869-B2 | Sulfonamide compounds as voltage-gated sodium channel modulators | SCN7A, SCN1A, SCN5A | CYP1A2 1590/4885CYP2C9 799/4885CYP2C19 1651/4885 |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | CYP1A2 430/4885CYP2C9 2887/4885CYP2C19 1681/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CYP1A2 2609/4885CYP2C9 2484/4885CYP2C19 1732/4885 |
| US-20180186777-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | SCN7A, SCN1A, SCN5A | CYP1A2 1590/4885CYP2C9 799/4885CYP2C19 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.